Abbott (ABT) Dips More Than Broader Market: What You Should Know

In the latest trading session, Abbott (ABT) closed at $101.88, marking a -2.03% move from the previous day. This move lagged the S&P 500's daily loss of 0.4%. At the same time, the Dow added 0.11%, and the tech-heavy Nasdaq lost 0.73%. The maker of infant formula, medical devices and drugs's stock has dropped by 10.62% in the past month, falling short of the Medical sector's loss of 10.07% and the S&P 500's loss of 7.34%.The upcoming earnings release of Abbott will be of great interest to investors. The company's earnings report is expected on April 16, 2026. The company is predicted to post an EPS of $1.15, indicating a 5.5% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $11.02 billion, reflecting a 6.38% rise from the equivalent quarter last year. For the full year, the Zacks Consensus Estimates project earnings of $5.68 per share and a revenue of $47.7 billion, demonstrating changes of +10.29% and +7.62%, respectively, from the preceding year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Abbott. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0% lower within the past month. Currently, Abbott is carrying a Zacks Rank of #3 (Hold). Digging into valuation, Abbott currently has a Forward P/E ratio of 18.32. This indicates a discount in contrast to its industry's Forward P/E of 18.43. Investors should also note that ABT has a PEG ratio of 1.65 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 1.52. The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 170, positioning it in the bottom 31% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Zacks.com. Free Report: Profiting from the 2nd Wave of AI ExplosionThe next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.Investors who bought shares like Nvidia at the right time have had a shot at huge gains.But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.Access AI Boom 2.0 now, absolutely free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks